Symbols / BPTH
BPTH Chart
About
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 642.33K |
| Enterprise Value | — | Income | -11.18M | Sales | — |
| Book/sh | -0.87 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | -0.08 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | 0.08 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -4.04 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 15:00 | ROA | -3.73% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.24M |
| Shs Float | 8.85M | Short Float | 1.38% | Short Ratio | 0.43 |
| Short Interest | — | 52W High | 0.36 | 52W Low | 0.05 |
| Beta | -0.22 | Avg Volume | 19.98K | Volume | 13.61K |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.07 | Change | 13.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.07
Latest analyst target
3. DCF / Fair value
$0.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.07
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-08 | reit | Roth MKM | Buy → Buy | $20 |
| 2024-04-18 | reit | Roth MKM | Buy → Buy | $40 |
| 2024-03-27 | main | Roth MKM | Buy → Buy | $40 |
- Bio-Path Holdings, Inc. Provides Update on Clinical Development Progress and Pipeline Advances - Nasdaq ue, 03 Jun 2025 07
- Bio-Path Holdings announces executive resignations and operational pause - Investing.com ue, 24 Jun 2025 07
- Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - Insider Monkey Wed, 04 Jun 2025 07
- All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy - Yahoo Finance Wed, 20 Nov 2024 08
- BPTH - Bio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan hu, 03 Sep 2020 17
- Bio-Path (BPTH) Stock Price, News & Analysis - MarketBeat Fri, 10 Jul 2015 14
- Bio-Path Holdings to be delisted from Nasdaq - Investing.com ue, 18 Feb 2025 08
- Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker - Bloomberg.com hu, 07 Mar 2019 08
- Bio-Path Earnings: BPTH Stock Moves on Q3 Results - InvestorPlace Fri, 15 Nov 2019 08
- When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)? - Yahoo Finance Sat, 17 Feb 2024 08
- Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs - TradingView Fri, 14 Jun 2024 07
- ROTH Capital Partners Acts as Sole Placement Agent for Bio-Path Holdings Offering - Pryor Cashman LLP hu, 18 Feb 2021 08
- Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference - Stock Titan ue, 03 Sep 2024 07
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress - Stock Titan Fri, 14 Jun 2024 07
- BPTH stock touches 52-week low at $0.84 amid sharp annual decline - Investing.com UK Wed, 06 Nov 2024 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.92M | -15.39M | -13.72M | -10.28M |
| TotalUnusualItems | 2.08M | -271.00K | ||
| TotalUnusualItemsExcludingGoodwill | 2.08M | -271.00K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.89M | -16.08M | -13.87M | -10.44M |
| ReconciledDepreciation | 159.00K | 178.00K | 178.00K | 161.00K |
| EBITDA | -11.83M | -15.66M | -13.72M | -10.28M |
| EBIT | -11.99M | -15.84M | -13.90M | -10.44M |
| NetInterestIncome | 14.00K | 36.00K | 33.00K | 3.00K |
| InterestIncome | 14.00K | 36.00K | 33.00K | 3.00K |
| NormalizedIncome | -11.98M | -15.81M | -13.87M | -10.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.89M | -16.08M | -13.87M | -10.44M |
| TotalExpenses | 11.99M | 15.84M | 13.90M | 10.44M |
| TotalOperatingIncomeAsReported | -11.99M | -15.84M | -13.90M | -10.44M |
| DilutedAverageShares | 2.40M | 478.00K | 364.00K | 336.25K |
| BasicAverageShares | 2.40M | 478.00K | 364.00K | 336.25K |
| DilutedEPS | -4.12 | -33.63 | -38.12 | -31.00 |
| BasicEPS | -4.12 | -33.63 | -38.12 | -31.00 |
| DilutedNIAvailtoComStockholders | -9.89M | -16.08M | -13.87M | -10.44M |
| NetIncomeCommonStockholders | -9.89M | -16.08M | -13.87M | -10.44M |
| NetIncome | -9.89M | -16.08M | -13.87M | -10.44M |
| NetIncomeIncludingNoncontrollingInterests | -9.89M | -16.08M | -13.87M | -10.44M |
| NetIncomeContinuousOperations | -9.89M | -16.08M | -13.87M | -10.44M |
| PretaxIncome | -9.89M | -16.08M | -13.87M | -10.44M |
| OtherIncomeExpense | 2.08M | -271.00K | ||
| GainOnSaleOfSecurity | 2.08M | -271.00K | ||
| NetNonOperatingInterestIncomeExpense | 14.00K | 36.00K | 33.00K | 3.00K |
| InterestIncomeNonOperating | 14.00K | 36.00K | 33.00K | 3.00K |
| OperatingIncome | -11.99M | -15.84M | -13.90M | -10.44M |
| OperatingExpense | 11.99M | 15.84M | 13.90M | 10.44M |
| ResearchAndDevelopment | 7.29M | 11.61M | 9.16M | 5.91M |
| SellingGeneralAndAdministration | 4.70M | 4.24M | 4.74M | 4.53M |
| GeneralAndAdministrativeExpense | 4.70M | 4.24M | 4.74M | 4.53M |
| OtherGandA | 4.70M | 4.24M | 4.74M | 4.53M |
| SalariesAndWages | 655.00K | 655.00K | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 5.77M | 617.63K | 398.00K | 358.00K |
| ShareIssued | 5.77M | 617.63K | 398.00K | 358.00K |
| TotalDebt | 83.00K | 113.00K | 221.00K | 235.00K |
| TangibleBookValue | 154.00K | 441.00K | 14.17M | 25.46M |
| InvestedCapital | 154.00K | 441.00K | 14.17M | 25.46M |
| WorkingCapital | 481.00K | 1.14M | 13.93M | 25.18M |
| NetTangibleAssets | 154.00K | 441.00K | 14.17M | 25.46M |
| CapitalLeaseObligations | 83.00K | 113.00K | 221.00K | 235.00K |
| CommonStockEquity | 154.00K | 441.00K | 14.17M | 25.46M |
| TotalCapitalization | 154.00K | 441.00K | 14.17M | 25.46M |
| TotalEquityGrossMinorityInterest | 154.00K | 441.00K | 14.17M | 25.46M |
| StockholdersEquity | 154.00K | 441.00K | 14.17M | 25.46M |
| RetainedEarnings | -117.50M | -107.61M | -91.53M | -77.66M |
| AdditionalPaidInCapital | 117.65M | 108.05M | 105.70M | 103.11M |
| CapitalStock | 6.00K | 1.00K | 1.00K | 7.00K |
| CommonStock | 6.00K | 1.00K | 1.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.73M | 2.78M | 1.80M | 1.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 434.00K | 873.00K | 113.00K | 153.00K |
| DerivativeProductLiabilities | 434.00K | 863.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 10.00K | 113.00K | 153.00K |
| LongTermCapitalLeaseObligation | 0.00 | 10.00K | 113.00K | 153.00K |
| CurrentLiabilities | 3.29M | 1.91M | 1.68M | 958.00K |
| CurrentDebtAndCapitalLeaseObligation | 83.00K | 103.00K | 108.00K | 82.00K |
| CurrentCapitalLeaseObligation | 83.00K | 103.00K | 108.00K | 82.00K |
| PayablesAndAccruedExpenses | 3.21M | 1.80M | 1.58M | 876.00K |
| CurrentAccruedExpenses | 1.94M | 1.35M | 909.00K | 770.00K |
| Payables | 1.27M | 457.00K | 667.00K | 106.00K |
| AccountsPayable | 1.27M | 457.00K | 667.00K | 106.00K |
| TotalAssets | 3.88M | 3.22M | 15.97M | 26.57M |
| TotalNonCurrentAssets | 107.00K | 178.00K | 356.00K | 428.00K |
| NetPPE | 107.00K | 178.00K | 356.00K | 428.00K |
| AccumulatedDepreciation | -1.05M | -1.04M | -962.00K | -874.00K |
| GrossPPE | 1.16M | 1.22M | 1.32M | 1.30M |
| Leases | 463.00K | 463.00K | 463.00K | 463.00K |
| OtherProperties | 565.00K | 583.00K | 679.00K | 663.00K |
| MachineryFurnitureEquipment | 133.00K | 176.00K | 176.00K | 176.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.78M | 3.04M | 15.62M | 26.14M |
| PrepaidAssets | 2.60M | 1.99M | 5.23M | 2.37M |
| CashCashEquivalentsAndShortTermInvestments | 1.17M | 1.05M | 10.38M | 23.77M |
| CashAndCashEquivalents | 1.17M | 1.05M | 10.38M | 23.77M |
| CashFinancial | 1.17M | 1.05M | 10.38M | 23.77M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.57M | -11.54M | -15.12M | -9.99M |
| IssuanceOfCapitalStock | 10.70M | 1.68M | 1.73M | 15.85M |
| CapitalExpenditure | -21.00K | -70.00K | ||
| EndCashPosition | 1.17M | 1.05M | 10.38M | 23.77M |
| BeginningCashPosition | 1.05M | 10.38M | 23.77M | 13.76M |
| ChangesInCash | 121.00K | -9.33M | -13.39M | 10.02M |
| FinancingCashFlow | 10.70M | 2.20M | 1.73M | 20.01M |
| CashFlowFromContinuingFinancingActivities | 10.70M | 2.20M | 1.73M | 20.01M |
| ProceedsFromStockOptionExercised | 0.00 | 526.00K | 0.00 | 4.16M |
| NetCommonStockIssuance | 10.70M | 1.68M | 1.73M | 15.85M |
| CommonStockIssuance | 10.70M | 1.68M | 1.73M | 15.85M |
| InvestingCashFlow | 0.00 | -21.00K | -70.00K | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -21.00K | -70.00K | |
| NetPPEPurchaseAndSale | 0.00 | -21.00K | -70.00K | |
| PurchaseOfPPE | 0.00 | -21.00K | -70.00K | |
| OperatingCashFlow | -10.57M | -11.54M | -15.10M | -9.92M |
| CashFlowFromContinuingOperatingActivities | -10.57M | -11.54M | -15.10M | -9.92M |
| ChangeInWorkingCapital | 678.00K | 3.36M | -2.26M | -459.00K |
| ChangeInOtherCurrentLiabilities | -118.00K | -108.00K | -99.00K | -95.00K |
| ChangeInOtherCurrentAssets | -171.00K | 286.00K | 199.00K | -915.00K |
| ChangeInPayablesAndAccruedExpense | 1.41M | 227.00K | 700.00K | -199.00K |
| ChangeInPrepaidAssets | -442.00K | 2.96M | -3.06M | 750.00K |
| StockBasedCompensation | 566.00K | 734.00K | 851.00K | 821.00K |
| DepreciationAmortizationDepletion | 159.00K | 178.00K | 178.00K | 161.00K |
| DepreciationAndAmortization | 159.00K | 178.00K | 178.00K | 161.00K |
| Depreciation | 159.00K | 178.00K | 178.00K | 161.00K |
| OperatingGainsLosses | -2.08M | 271.00K | ||
| GainLossOnInvestmentSecurities | -2.08M | 271.00K | ||
| NetIncomeFromContinuingOperations | -9.89M | -16.08M | -13.87M | -10.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BPTH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|